Free Trial Information
BioCentury | Aug 8, 2019
Translation in Brief

A cool menthol switch for gene expression

ETH Zurich researchers have created a synthetic gene circuit activated by topical menthol to switch on gene expression and protein production in engineered cells. In a July Nature Medicine paper , the team used the circuit...
Read More
BioCentury | Aug 8, 2019
Distillery Therapeutics

Engineered cells with a synthetic gene switch for diabetes

DISEASE CATEGORY: Endocrine/Metabolic INDICATION: Diabetes Engineered cells with a synthetic gene circuit could treat diabetes. The system comprises implanted HEK cells encoding a synthetic calcium-responsive promoter and the insulin gene. In Type I diabetic mice,...
Read More
BioCentury | Jun 28, 2018
Translation in Brief

Synchronous signaling

As researchers explore next-generation CARs in cancer, one strategy is to tinker with the receptors’ modular components. A Science Signaling paper suggests that altering the number of ITAM repeats in the intracellular domains of a...
Read More
BioCentury | Feb 1, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: January 2018

...could help treat obesity-related insulin resistance. Max Planck Institute for Metabolism Research Distillery Therapeutics Diabetes Nuclear factor of activated T cells 5...
Read More
BioCentury | Jan 23, 2018
Distillery Therapeutics

Endocrine / Metabolic

...mir-181a or NFAT5 prevents progression to Type I diabetes in animal models. TARGET/MARKER/PATHWAY: MicroRNA-181a (miR-181a); nuclear factor of activated T cells 5...
...Daniel, Helmholtz Diabetes Center at Helmholtz Zentrum München, Munich, Germany email: carolin.daniel@helmholtz-muenchen.de Hongjiang Li Helmholtz Zentrum Muenchen MicroRNA-181a (miR-181a) Nuclear factor of activated T cells 5...
Read More
BioCentury | Jun 30, 2016
Distillery Therapeutics

Therapeutics: Nuclear factor of activated T cells cytoplasmic calcineurin-dependent 1 (NFATc1); interleukin-10 (IL-10)

Autoimmune disease INDICATION: Psoriasis Mouse studies suggest inhibiting NFATc1 could help treat psoriasis. In a mouse model of psoriasis, knockout of NFATc1 in B cells increased IL-10 production in the spleen, decreased the number of...
Read More
BioCentury | Apr 14, 2016
Distillery Therapeutics

Therapeutics: Nuclear factor of activated T cells cytoplasmic calcineurin-dependent 3 (NFATc3; NFAT4); protein phosphatase 3 regulatory subunit B α (PPP3R1)

Cancer INDICATION: Colorectal cancer Patient sample and mouse studies suggest inhibiting NFATc3 or PPP3R1 could help treat colorectal cancer (CRC). In CRC patients, NFATc3 nuclear activity in tumor cells correlated with poor survival and NFATc3...
Read More
BioCentury | Feb 18, 2016
Distillery Therapeutics

Therapeutics: Nuclear factor of activated T cells cytoplasmic calcineurin-dependent 3 (NFATc3; NFAT4)

Inflammation INDICATION: Shock / trauma Rat studies suggest inhibiting NFATc3 could help treat traumatic brain injury (TBI). In a rat model of TBI, NFATc3 and astrocytes co-localized in the hippocampus seven days post-injury. In hippocampal...
Read More
BioCentury | May 21, 2015
Targets & Mechanisms

Intersection in marrow

An unlikely connection between Gaucher's disease and multiple myeloma has been uncovered by a U.K. group that found a common node in the pathways responsible for the bone disease symptoms that accompany both diseases. Suppression...
Read More
BioCentury | May 8, 2014
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Pancreatic cancer Nuclear factor of activated T cells cytoplasmic calcineurin-dependent 1 (NFATc1) In vitro and mouse studies suggest inhibiting NFATc1 could help treat pancreatic cancers....
Read More
Items per page:
1 - 10 of 23